ERBB2 and breast carcinoma: Two ongoing trials offer future perspectives for stage I HER2-positive breast cancer: ATEMPT 2.0 (NCT04893109), evaluating a shorter exposure to T-DM1 regimen (six cycles), and the phase II ADEPT trial (NCT04569747), a phase II study exploring a chemotherapy-free regimen combining endocrine therapy with subcutaneous trastuzumab and pertuzumab for patients with HER2-positive breast cancer expressing hormone receptors.